Abstract:Herpes simplex virus type 1 (HSV1) is a complicated structural agent with a sophisticated transcription process and a high infection rate. A vaccine against HSV1 is urgently needed. As multiple viral-encoded proteins, including structural and nonstructural proteins, contribute to immune response stimulation, an attenuated or deficient HSV1 vaccine may be relatively reliable. Advances in genomic modification technologies provide reliable means of constructing various HSV vaccine candidates. Based on our previous work, an M6 mutant with mutations in the UL7, UL41, LAT, Us3, Us11 and Us12 genes was established. The mutant exhibited low proliferation in cells and an attenuated phenotype in an animal model. Furthermore, in mice and rhesus monkeys, the mutant can induce remarkable serum neutralizing antibody titers and T cell activation and protect against HSV1 challenge by impeding viral replication, dissemination and pathogenesis.Herpes simplex virus type 1 (HSV1) may lead to various herpes infections and can establish latent infection in neurons, which shows a high infectivity rate in populations. There is currently no effective therapeutic and prophylactic vaccine against HSV1. Previous studies have indicated that attenuated or deficient HSV1 vaccines are capable of safely eliciting a comprehensive protective immune response. With the advances in genomic modification technologies and accumulated knowledge of viral-encoded proteins, various predictable vaccine candidates can be reliably designed. In this work, a mutant M6 containing mutations in the UL7, UL41, LAT, Us3, Us11 and Us12 genes was established. Furthermore, the proliferation characteristics, virulence phenotype and immunogenicity of the mutant were analyzed in different cells and in mice and rhesus macaques.

Further Investigation of Nonspecific Biological Substance in Anti‐Rh(D) Preparations

[Mechanisms of Herpes Simplex Virus Latency and Reactivation].

A review of HSV pathogenesis, vaccine development, and advanced applications

Clinical management of herpes simplex virus infections: past, present, and future

A family 11 xylanase from Penicillium funiculosum is strongly inhibited by three wheat xylanase inhibitors.

Immune Response to Herpes Simplex Virus Infection and Vaccine Development

Vaccine value profile for herpes simplex virus

Integrating pan-genome and reverse vaccinology to design multi-epitope vaccine against Herpes simplex virus type-1

The Quest for Immunity: Exploring Human Herpesviruses as Vaccine Vectors

Targeting herpesvirus entry complex and fusogen glycoproteins with prophylactic and therapeutic agents

An updated review of HSV-1 infection-associated diseases and treatment, vaccine development, and vector therapy application

A HSV1 mutant leads to an attenuated phenotype and induces immunity with a protective effect

Toll‐like Receptors As Novel Therapeutic Targets for Herpes Simplex Virus Infection

Current Antivirals and Novel Botanical Molecules Interfering With Herpes Simplex Virus Infection

Therapeutic vaccines for herpesviruses

Construction, Identification, and Immunogenic Assessments of an HSV-1 Mutant Vaccine with a UL18 Deletion.

Vaccines for STIs: Present and Future Directions

EBP50 interacts with EGFR and regulates EGFR signaling to affect the prognosis of cervical cancer patients.

Rigler sign: an underappreciated alert for pneumoperitoneum.

Advances and prospect in herpesviruses infections after haematopoietic cell transplantation: closer to the finish line?

The immunobiology of corneal HSV-1 infection and herpetic stromal keratitis